{"filing":{"accession_number":"0001599298-26-000052","cik":"0001599298","ticker":"SMMT","company_name":"Summit Therapeutics Inc.","form":"8-K","filing_date":"2026-06-11","report_date":null,"primary_document":"smmt-20260610.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1599298/000159929826000052/smmt-20260610.htm"},"events":[{"id":5485,"run_id":4808,"accession_number":"0001599298-26-000052","anchor_item_number":"7.01","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"summary":"Summit Therapeutics withdrew a previously announced underwritten public offering effective June 10, 2026 due to market conditions. While the withdrawal itself is disclosed under Item 7.01 (Other Events), the cancellation of a planned capital raise signals material market or financial stress that would affect investor assessment of the company's liquidity and strategic position. This does not fit neatly into the dilutive_issuance category (which covers completed or announced offerings) but represents a material change in the company's financing plans.","company_name":"Summit Therapeutics Inc.","ticker":"SMMT","filing_date":"2026-06-11","form":"8-K","submitted_at":null,"items":[{"id":6091,"accession_number":"0001599298-26-000052","item_number":"7.01","item_title":null,"event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"reasoning":"Summit Therapeutics withdrew a previously announced underwritten public offering effective June 10, 2026 due to market conditions. While the withdrawal itself is disclosed under Item 7.01 (Other Events), the cancellation of a planned capital raise signals material market or financial stress that would affect investor assessment of the company's liquidity and strategic position. This does not fit neatly into the dilutive_issuance category (which covers completed or announced offerings) but represents a material change in the company's financing plans.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-11T11:45:06.608715+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":6091,"accession_number":"0001599298-26-000052","item_number":"7.01","item_title":null,"event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"reasoning":"Summit Therapeutics withdrew a previously announced underwritten public offering effective June 10, 2026 due to market conditions. While the withdrawal itself is disclosed under Item 7.01 (Other Events), the cancellation of a planned capital raise signals material market or financial stress that would affect investor assessment of the company's liquidity and strategic position. This does not fit neatly into the dilutive_issuance category (which covers completed or announced offerings) but represents a material change in the company's financing plans.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-11T11:45:06.608715+00:00","company_name":"Summit Therapeutics Inc.","ticker":"SMMT","filing_date":"2026-06-11"}]}